Cerebrovascular disease drug pipelines

Dainippon Sumitomo Pharma

SB623

Chronic stroke

Phase II


Sanofi

patisiran

Familial amyloidotic polyneuropathy

siRNA inhibitor targeting TTR

Phase III


Johnson & Johnson

rivaroxaban

Stroke (secondary prevention)

Phase III


Biogen

natalizumab

Stroke (acute ischemic)

α4-integrin inhibitor

Phase II


Sunovion

SB-623

Stroke (chronic)

Phase II


Acorda Therapeutics

Dalfampridine

Stroke

Phase III